ORTINGLOBE · Ortin Global Ltd · Biotechnology & Drugs
ORTINGLOBE · Ortin Global Ltd · Biotechnology & Drugs
As of 06 Nov close
52-week range
38.9% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 53 days old
Revenue (latest Q)
₹0.01 Cr
Revenue YoY
PAT YoY
-88.9%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
11.6
P/S (TTM)
192.2
Sector P/E
36.3
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| ORTINGLOBE (this stock) | Not meaningful (earnings negative over the last 12 months) | 11.6 | -1500.0% | -72.6% | 0.81 | 0.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
rising 1q
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| canonicalSymbol | date | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| ORTINGLOBE | 2026-09-08 | 44683 | 1 | STRONG | BULK |
| ORTINGLOBE | 2026-07-10 | 0 | 0 | WEAK | BULK |
| ORTINGLOBE | 2026-06-08 | 50000 | 1 | STRONG | BULK |
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedThe report outlines key corporate governance and operational updates for Ortin Global Limited, including changes in director designations, compliance with regulatory requirements, and strategic focus on business expansion. The company is in the phase of business expansion, which has led to initial financial challenges, but management expects improvement in the coming years. The report emphasizes adherence to corporate governance standards, board evaluations, and the appointment of new directors to strengthen leadership and strategic direction.
- Changes in director designations, including the transition of Mr. Murali Krishna Murthy Sanka from Managing Director to Non-Executive Director and Mr. Prashant Prakash Sawant to Managing Director.
- Commitment to corporate governance, including board evaluations, independent director familiarization programs, and compliance with SEBI and Companies Act regulations.
- Strategic focus on business expansion, with management acknowledging initial financial challenges due to upfront investments but management expects improved financial performance in the coming years.
Key takeaway: The company is undergoing strategic leadership changes and expansion, with a focus on corporate governance and long-term financial improvement despite current challenges.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Auditor Qualification (1 item); Regulatory Action (2 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Auditor Qualification
1 occurrenceEarlier (1-3 years ago)
The auditor highlights key audit matters including the company's net worth erosion exceeding 50%, cash losses, revision of financial statements for compliance with Schedule III of the Companies Act 2013, and cancellation of the manufacturing license due to non-compliance.
Regulatory Action
2 occurrencesEarlier (1-3 years ago)
The company has not appointed the Company Secretary and Compliance officer, leading to regulatory action by BSE and NSE in FY 2024-25.
The company was asked to pay a penalty of Rs. 53,100 for delayed submission of audited financial results to the Stock Exchanges, and has since paid the penalty on 10.03.2022.
Routine disclosures
Contingent Liability
2 occurrencesEarlier (1-3 years ago)
The company has GST demands for the financial years 2017-18, 2018-19, 2019-20 as contingent liabilities.
The company has GST demands for financial years 2017-18 to 2020-21 amounting to Rs. 2,432.00 Lakhs, with appeals either filed or pending. TDS notices for financial years 2008-09 to 2023-24 amounting to Rs. 1.88 Lakhs are also mentioned.
Related-Party Transaction
2 occurrencesEarlier (1-3 years ago)
The company entered into related-party transactions with its directors, involving unsecured loans repaid by the company, with amounts totaling Rs. 6.60 Lakhs and Rs. 48.00 Lakhs for S. Murali Krishna Murthy and Rs. 24.00 Lakhs for S. Balaji Venkateshwarlu.
The company entered into related-party transactions with its directors, including unsecured loans taken and repaid, with amounts totaling Rs. 6.60 Lakhs, 6.67 Lakhs, and Rs. 59.82 Lakhs respectively, approved by the board on 30.05.2023.
Management & Board Governance
1 occurrenceEarlier (1-3 years ago)
The Company Secretary and Compliance Officer, Mr. Nitesh Kumar Sharma, resigned effective 12.06.2023. Subsequently, Mr. Harish Sharma was appointed but also resigned effective 10.11.2023. Ms. Divya Purswani was appointed on 09.02.2024 but resigned effective 18.07.2024. As of the report date, Mr. S. Murali Krishna Murthy Sanka, Managing Director, is serving as the compliance officer.